← Therapy pipeline
Investigational · Obesity development

Cagrilintide

Novo Nordisk

Standalone amylin analogue, distinct from its CagriSema combination.

amylin
Other study areas
Pediatric weight management
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorNovo Nordisk
Targetsamylin
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

REDEFINE 1 · cagrilintide monotherapy armMean body-weight reductionBody weight decreased 11.8% · 68 weeks · Phase 3
Phase 3 · Injection · Sponsor-reported numerical results

Mean body-weight reduction · 68 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
11.8%
Placebo / comparator
2.3%

Adults without type 2 diabetes; parent trial N includes all four arms · Cagrilintide 2.4 mg once weekly vs placebo · Trial N=3417 · Adherence-based estimate; sponsor-reported subanalysis. Results & methods ↗

This is the monotherapy arm of the CagriSema parent trial, not a RENEW result. The estimate assumes treatment adherence; Phase 2 dose-finding results remain below.

Standalone dose-finding trialMean body-weight reductionBody weight decreased 10.8% · 26 weeks · Phase 2
Phase 2 · Injection · Peer-reviewed results

Mean body-weight reduction · 26 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
10.8%
Placebo / comparator
3%

Adults with obesity or overweight and a weight-related complication, without diabetes · 4.5 mg once weekly vs placebo · Trial N=706 · Trial-product estimand. Results & methods ↗

This is standalone cagrilintide, not CagriSema. The trial also included liraglutide 3 mg, with 9.0% mean reduction.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1—
GIPGIP—
GCGglucagon—
AMYamylinTargeted
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 3RENEW 1 initiated
Milestone → next

Latest: RENEW 1 Phase 3 monotherapy trial registered.

Next: RENEW efficacy and safety readouts.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies3 records

Phase 3

Cagrilintide / CagriSema · pediatric study

Pediatric weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Shared protocol evaluating cagrilintide and CagriSema in children/adolescents; one protocol linked from both relevant profiles. Investigational pediatric use.

Phase 3

REDEFINE 1 · cagrilintide monotherapy arm

Weight management without type 2 diabetes
Study: OngoingResults: Sponsor results shown aboveStatus reviewed November 2026

Monotherapy arm within the four-arm parent trial; 2.4 mg cagrilintide versus placebo. Same registered study as the CagriSema profile, not a separate RENEW trial.

Phase 3

RENEW 1

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Standalone cagrilintide monotherapy study for chronic weight management.

Phase 2 studies1 record

Phase 2

Standalone cagrilintide dose-finding study

Weight management
Study: CompletedResults: Published results linked aboveStatus reviewed November 2026

Published dose-ranging monotherapy study in adults with obesity or overweight and a weight-related complication, without diabetes. The cagrilintide arm within REDEFINE 1 is not a separate standalone trial.